Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team.

Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527.

PMID:
25266426
2.

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.

Bastiaans DE, Forcat S, Lyall H, Cressey TR, Hansudewechakul R, Kanjanavanit S, Noguera-Julian A, Königs C, Inshaw JR, Chalermpantmetagul S, Saïdi Y, Compagnucci A, Harper LM, Giaquinto C, Colbers AP, Burger DM; PENTA 18KONCERT Study Group.

Pediatr Infect Dis J. 2014 Mar;33(3):301-5. doi: 10.1097/INF.0000000000000014.

PMID:
24356253
3.

The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team.

PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013.

4.

Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.

Bunupuradah T, Duong T, Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A, Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA 11 Extension Study Group.

AIDS. 2013 Feb 20;27(4):579-89. doi: 10.1097/QAD.0b013e32835c1181.

PMID:
23135172
5.

Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.

Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team.

AIDS Behav. 2013 Jan;17(1):193-202. doi: 10.1007/s10461-012-0197-y.

6.

Involvement of consumers in studies run by the Medical Research Council Clinical Trials Unit: results of a survey.

Vale CL, Thompson LC, Murphy C, Forcat S, Hanley B.

Trials. 2012 Jan 13;13:9. doi: 10.1186/1745-6215-13-9.

7.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS.

Lancet Infect Dis. 2011 Apr;11(4):273-83. doi: 10.1016/S1473-3099(10)70313-3. Epub 2011 Jan 31.

8.

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.

Paediatric European Network for Treatment of AIDS (PENTA).

Antivir Ther. 2010;15(3):297-305. doi: 10.3851/IMP1532.

9.

The metabolic transition during disease following infection of Arabidopsis thaliana by Pseudomonas syringae pv. tomato.

Ward JL, Forcat S, Beckmann M, Bennett M, Miller SJ, Baker JM, Hawkins ND, Vermeer CP, Lu C, Lin W, Truman WM, Beale MH, Draper J, Mansfield JW, Grant M.

Plant J. 2010 Aug;63(3):443-57. doi: 10.1111/j.1365-313X.2010.04254.x. Epub 2010 May 18.

PMID:
20497374
10.

Rapid linkage of indole carboxylic acid to the plant cell wall identified as a component of basal defence in Arabidopsis against hrp mutant bacteria.

Forcat S, Bennett M, Grant M, Mansfield JW.

Phytochemistry. 2010 Jun;71(8-9):870-6. doi: 10.1016/j.phytochem.2010.03.010. Epub 2010 Mar 30.

PMID:
20359727
11.

Agroinfiltration reduces ABA levels and suppresses Pseudomonas syringae-elicited salicylic acid production in Nicotiana tabacum.

Rico A, Bennett MH, Forcat S, Huang WE, Preston GM.

PLoS One. 2010 Jan 29;5(1):e8977. doi: 10.1371/journal.pone.0008977.

12.

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS.

AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.

PMID:
20010073
13.

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D.

HIV Med. 2009 Nov;10(10):591-613. doi: 10.1111/j.1468-1293.2009.00759.x.

PMID:
19878352
14.

A rapid and robust method for simultaneously measuring changes in the phytohormones ABA, JA and SA in plants following biotic and abiotic stress.

Forcat S, Bennett MH, Mansfield JW, Grant MR.

Plant Methods. 2008 Jun 30;4:16. doi: 10.1186/1746-4811-4-16.

15.

Stabilisation of transition states prior to and following eudesmane cation in aristolochene synthase.

Forcat S, Allemann RK.

Org Biomol Chem. 2006 Jul 7;4(13):2563-7. Epub 2006 May 25.

PMID:
16791319
16.

Dual role for phenylalanine 178 during catalysis by aristolochene synthase.

Forcat S, Allemann RK.

Chem Commun (Camb). 2004 Sep 21;(18):2094-5. Epub 2004 Aug 6.

PMID:
15367991
17.

Stabilisation of eudesmane cation by tryptophan 334 during aristolochene synthase catalysis.

Deligeorgopoulou A, Taylor SE, Forcat S, Allemann RK.

Chem Commun (Camb). 2003 Sep 7;(17):2162-3.

PMID:
13678181
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk